[go: up one dir, main page]

WO2019088541A2 - Composition contenant un extrait de salvia miltiorrhiza pour la prévention, la réduction ou le traitement de l'obésité viscérale - Google Patents

Composition contenant un extrait de salvia miltiorrhiza pour la prévention, la réduction ou le traitement de l'obésité viscérale Download PDF

Info

Publication number
WO2019088541A2
WO2019088541A2 PCT/KR2018/012522 KR2018012522W WO2019088541A2 WO 2019088541 A2 WO2019088541 A2 WO 2019088541A2 KR 2018012522 W KR2018012522 W KR 2018012522W WO 2019088541 A2 WO2019088541 A2 WO 2019088541A2
Authority
WO
WIPO (PCT)
Prior art keywords
extract
obesity
visceral fat
composition
fat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2018/012522
Other languages
English (en)
Korean (ko)
Other versions
WO2019088541A3 (fr
Inventor
윤주석
김누리
손정환
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Huen Co ltd
Original Assignee
Huen Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020180125449A external-priority patent/KR102005423B1/ko
Application filed by Huen Co ltd filed Critical Huen Co ltd
Priority to CN201880031146.9A priority Critical patent/CN110612111A/zh
Priority to JP2019565315A priority patent/JP2021501119A/ja
Priority to EP18873842.1A priority patent/EP3705127A4/fr
Priority to US16/615,148 priority patent/US20200171115A1/en
Publication of WO2019088541A2 publication Critical patent/WO2019088541A2/fr
Publication of WO2019088541A3 publication Critical patent/WO2019088541A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537—Salvia (sage)

Definitions

  • the present invention relates to a preventive, ameliorative or therapeutic composition for visceral fat-type obesity which contains extracts of Panax ginseng having excellent activity against visceral fat loss.
  • the present invention relates to a method for preventing obesity in visceral obesity comprising administering to a model animal mouse and obesity-inducing DIO (dietinducedobesity) mice caused by obesity due to a decrease in leptin secretion, , ≪ / RTI >
  • Obesity is a disease that increases the risk of obesity as well as constipation, indigestion, and gastrointestinal disorders due to abdominal stress due to adipose tissue.
  • Typical examples of such diseases are type 2 diabetes, hypertension, coronary artery disease, stroke and various cancers (cancer) can cause the disease is very dangerous.
  • Fat which is the main cause of obesity, acts as a sort of warehouse that stores in vivo surplus energy and supplies it when needed.
  • the fat is divided into subcutaneous fat and visceral fat.
  • the subcutaneous fat maintains the body temperature constantly and acts as an insulator (insulation), so it has tolerance to the cold. Generally, the higher the body fat percentage, the stronger the cold. In addition, it absorbs moisture and keeps it moist and soft.
  • Vitamins A, D, E, K and vitamins as a carrier of the sex hormone is also used as a precursor.
  • visceral fat unlike subcutaneous fat, is a major cause of metabolic diseases such as type 2 diabetes, hypertension and fatty liver by triggering insulin resistance. Secondarily, it causes vascular diseases such as heart disease and stroke, It provides neurodegenerative diseases such as arthritis and causes of aging.
  • Metabolic Syndrome which is directly linked to visceral fat, is a syndrome in which risk factors such as hypertriglyceridemia, hypertension, glucose metabolism, blood clotting abnormality, and obesity coexist.
  • NASH III National Cholesterol Education Program
  • 1 the abdominal obesity with a waist circumference of 40 inches (102 cm) for men and 35 inches (88 cm) for women
  • 3 HDL cholesterol is 40 mg / dL for male
  • 4 Blood pressure is 130/85 mmHg or higher
  • 5 Fasting glucose is 110 mg / dL or more. If the patient shows more than three, it is judged to be a metabolic disease.
  • Factors known to be associated with metabolic syndrome cause and treatment include sex hormones such as exercise, dietary habits, weight, blood sugar, triglyceride, cholesterol, insulin resistance, adiponectin, leptin, AMPK activity, estrogen, Factors, and malonyl-CoA in vivo concentrations are directly or indirectly involved.
  • Activation factors associated with metabolic activation include AMP-activated protein kinase, PGC-1 ⁇ , GLUT 1 and 4 (Glucose transporter), CPT1 (carnitine palmitoyltransferase 1), UCP-1 , 2, 3 (uncoupling protein), ACC I, II (acetyl-CoA carboxylase) and they play an important role in energy metabolism.
  • NQO1 NQO1
  • NQO1 quinone oxidoreductase
  • This pharmacological mechanism activates glucose metabolism, mitochondrial biosynthesis and lipid metabolism by inducing cytosolic energy uncoupling and changing the biooxidative redox status, which is the ratio of intracellular NAD + / NADH.
  • the increase in the ratio of intracellular NAD + / NADH is related to the long-term calorie restriction such as AMPK activation, anti-aging and anti-stress mechanism, sirtuin gene expression, PGC1a expression that activates energy metabolism of mitochondria, And genetic changes that occur during exercise.
  • DP dipeptidyl peptidase
  • apoA-I isoform and related peptides, CETP (Cholesterol ester transport protein) inhibitors which are targets of blood pressure treatment and hyperlipemia therapy, are attracting attention.
  • Weight loss a common method of eliminating obesity, is a reduction in body mass, such as body water, body fat, muscle and other tissue levels.
  • Unintended weight loss means weight loss in the absence of self-control of weight control, such as dietary control or exercise.
  • the percentage of body fat to body weight is normally 10 to 20% for men and 18 to 28% for women.
  • the ratio of visceral fat to subcutaneous fat varies according to the degree of obesity and the amount of exercise, and when it becomes an adult, obesity often leads to excessive visceral fat and increased abdominal fat percentage.
  • Obesity caused by visceral fat is known to cause adult diseases such as hypertension, cardiovascular disease, and diabetes. This is because the subcutaneous fat is far away from the center of the human body and oxygen is transferred by the microvessels, while the visceral fat is connected to the relatively large blood vessels and the fluidity of the fat is high.
  • the Applicant has thus found a composition for preventing, ameliorating or treating visceral fat type obesity which has no side effects and has an effect on visceral fat using Salvia miltiorrhiza Bunge extract.
  • Salvia miltiorrhiza Bunge is a medicinal herb belonging to genus Salvia of Lamiaceae. It is also called oriental herb, herbaceous herb, parsley, And go into the liver and blood vessels, hemorrhoids, and has the efficacy of receiving blood.
  • It removes the eosinophil from the human body and makes the circulation of the blood easier. It is a pharmacological agent for alleviating limb pain, irreversible menstrual irregularities, menstrual cramps, postpartum abdominal pain, hyperlipidemia, heart disease and brain diseases. Therefore, it has shown activity against cardiovascular and various vascular diseases, suppression of liver, lung and kidney damage, activity against osteoporosis, central nervous system effect, anti-inflammation, antioxidant and anti-cancer activity.
  • Korean Patent Registration No. 10-0818586 discloses' a therapeutic agent for obesity and metabolic syndrome which contains a tanshin derivative which promotes metabolism activity as an active ingredient.
  • the pharmaceutical composition of the present invention contains a pharmaceutically effective amount of the above mixture and can be used for the treatment of obesity, diabetes, arteriosclerosis, hypertension, hyperlipidemia, liver disease, stroke, myocardial infarction, ischemic diseases and cardiovascular diseases In a group of It is described as a composition for preventing or treating a selected one or more of metabolic syndrome disorders ".
  • the present inventor has found that the extract of Dansamp extract acts as a substrate of NQO1 to oxidize NADH in the cytoplasm to NAD to increase the ratio of NAD + / NADH in the cytoplasm and the reduced substrate transports electrons to the electron transport system of mitochondria to form ATP
  • the present inventors completed the present invention by studying the energy metabolizing activity that promotes the production and promote the recycling reaction, and further, in order to prove the prevention, improvement or therapeutic effect of visceral fat type obesity, Respectively.
  • a technical object of the present invention is to provide a composition for preventing, ameliorating or treating visceral fat-type obesity, which comprises a tea ginseng extract exhibiting excellent activity in reducing visceral fat.
  • the object of the present invention is to provide a method for the treatment of obesity, which comprises administering a single extract to a model animal mouse which causes obesity due to a decrease in leptin secretion, and DIO (dietinducedobesity) mice induced by a high fat diet, To provide a composition for preventing, ameliorating or treating visceral obesity.
  • the present invention aims at solving the technical problem by providing a composition for preventing, ameliorating or treating visceral fat type obesity containing the extract of Panax ginseng.
  • the present invention relates to a composition for preventing, ameliorating or treating visceral fat-type obesity, wherein the extract is extracted from any one selected from the group consisting of water, 1 to 6 carbon alcohols, and a mixed solvent thereof. To solve technical problems.
  • the present invention relates to a method of inhibiting the production of triglyceride (TG) in blood and liver tissue by administering the extract of Dansamp extract to a mouse (DIO: diet induced obesity mice) aminotransferase, GPT, glutamic pyruvate transaminase, LDH (lactate dehydrogenase), BUN (blood urea nitrogen), FFA (free fatty acid) or Hb A1C (glycosylated Hb)
  • the present invention provides a composition for improving or treating cancer.
  • the present invention relates to a method for the treatment of diarrhea, which comprises administering the extracts of the present invention to a subject in a diet-induced obesity mouse (DIO) in a high fat diet mode, followed by magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS)
  • DIO diet-induced obesity mouse
  • MRI magnetic resonance imaging
  • MRS magnetic resonance spectroscopy
  • the present invention provides a composition for preventing, ameliorating or treating visceral fat type obesity characterized by reduction of visceral fat and reduction of fat in liver tissue as a result of oil red O staining.
  • the present invention aims to solve the technical problem by providing a root extract and a mineral mixture comprising a root extract and at least one minerals selected from chromium, manganese, magnesium, zinc, copper or calcium.
  • the present invention relates to a method for preventing or ameliorating diseases mediated by visceral fat selected from the group consisting of hypertriglyceridemia, fatty liver, hypertension, diabetes, hyperlipidemia, cerebrovascular disease, glucose metabolism disorder, Or a therapeutic composition for the purpose of solving the technical problem.
  • visceral fat selected from the group consisting of hypertriglyceridemia, fatty liver, hypertension, diabetes, hyperlipidemia, cerebrovascular disease, glucose metabolism disorder, Or a therapeutic composition for the purpose of solving the technical problem.
  • the present invention aims at solving the technical problem by providing a health functional food composition for preventing or ameliorating visceral fat type obesity, which comprises Asa extract as an active ingredient.
  • the present invention aims at solving the technical problem by providing a health functional food composition for preventing or ameliorating visceral fat type obesity containing 0.1 to 50% of Radix extract.
  • the present invention provides a preventive, ameliorative, or therapeutic composition for visceral fat-type obesity, which comprises extracts of Panax ginseng.
  • the inhibitory effect of ginseng extract on visceral fat-type obesity inhibits the production of triglyceride TG in liver tissue and blood in vivo and inhibits the production of ALT, LDH, BUN, FFA or Hb A1C
  • the present invention can provide a preventive, ameliorative, or therapeutic composition for visceral fat-type obesity containing the extract of Panax ginseng through reduction of expression and visceral fat-reducing effect through MRI and MRS observation.
  • composition containing the extract of Panax ginseng at the time of necessitating a natural product visceral fat reducing agent without side effects can be developed as a food, cosmetic and pharmaceutical composition capable of preventing, improving or treating visceral fat type obesity.
  • FIG. 1 is a graph showing changes in triglyceride in blood and liver tissues when the extract of Panax ginseng is administered to C57BL / 6JL Lep ob / Lep ob, a genetic obesity model animal.
  • FIG. 2 is a graph showing changes in blood GPT (glutamic pyruvate transaminase), LDH (lactate dehydrogenase) and BUN (blood urea nitrogen) upon administration of the extract of Chenopodium ambrosioides L. at the C57BL / 6JL Lep ob / Lep ob genetic obesity model animal.
  • GPT glutamic pyruvate transaminase
  • LDH lactate dehydrogenase
  • BUN blood urea nitrogen
  • FIG. 3 is a graph showing changes in visceral visceral fat and lipid in liver tissues upon administration of the extract of Chenopodium ambrosioides L. to C57BL / 6JL Lep ob / Lep ob.
  • FIG. 4 is a graph showing a decrease in GPT (glutamic pyruvate transaminase), LDH (lactate dehydrogenase) and BUN (blood urea nitrogen) in the case of administration of the extract of Dansamp to DIO (diet-induced obesity)
  • GPT glutamic pyruvate transaminase
  • LDH lactate dehydrogenase
  • BUN blood urea nitrogen
  • FIG. 5 is a graph showing changes in visceral visceral fat and lipid in liver tissues upon administration of Dansamp extract to diet-induced obesity (DIO), which is an induction obesity model animal.
  • DIO diet-induced obesity
  • FIG. 6 is a graph showing change in TG in liver tissue and blood, free fatty acid in blood, and HbA1C during the administration of the extract of Chenopodium ambrosioides (DIO) to diet-induced obesity (DIO).
  • DIO Chenopodium ambrosioides
  • the extraction method from Danshen comprises the steps of: a) obtaining a crude extract by extracting with water or an organic solvent, b) filtering the crude extract, and then concentrating the extract, and c) concentrating and drying the extract to obtain various formulations And a step of fabricating.
  • Extracting the persimmon extract with hot water or 20 to 100% by weight ethanol is also used.
  • other solvents may be used.
  • Extraction solvents include water, ethanol, methanol, fatty oils, glycerin, mayo, ethyl acetate, acetone, butanol, isopropanol and methylene chloride.
  • the extract is heated at 40 to 80 ° C by a microwave drying method to remove moisture.
  • a step of concentrating and drying the extract by a low-temperature vacuum drying method is a method in which the pressure inside the dryer is maintained at a vacuum and the temperature is adjusted to about 5 to 15 ° C to dry it. There is no denaturation of the extracted components, and no taste or fragrance is lost.
  • methods such as spray drying, cold air drying, hot air drying, freeze drying, far infrared ray drying, negative drying, and vacuum drying may be used.
  • the extract is concentrated and dried by spray drying to prepare various formulations.
  • it can be prepared as a powder.
  • Low-temperature vacuum drying is a method in which the pressure inside the dryer is maintained at a vacuum and the temperature is adjusted to about 5 to 15 ° C to dry it. There is no denaturation of the extracted components, and no taste or fragrance is lost.
  • methods such as cold air drying, hot air drying, freeze drying, far infrared ray drying, negative drying, and vacuum drying may be used.
  • S. miltiorrhza was eluted with 50 L of ethanol for 24 hours and then concentrated under reduced pressure. To this was added 1500 ml of water, and the same amount of n-hexane, dichloromethane (CH2Cl2) and ethyl acetate (EtOAc) was added, and the mixture was repeatedly extracted twice to prepare a red ginseng extract of reddish color.
  • CH2Cl2 dichloromethane
  • EtOAc ethyl acetate
  • Nuclear magnetic resonance (NMR) analysis was performed to determine the structures of cryptotansinone, tanshinone I, tanshinone II A, and 15,16-dihydrotanshinone I, which are effective components of the extract of Radix Root Extract, Respectively.
  • NMR Nuclear magnetic resonance
  • Salvianolic acid, Tanshinone IIB, Hydrotanshinone and Tanshinoic acid and other tanshinones are contained in the extract.
  • C57BL / 6JL Lep ob / Lep ob mice of genetic obesity model were maintained at 20 °C ⁇ 2 °C and 60% ⁇ 10% at room temperature.
  • the environmental conditions of the animal breeding room were maintained. Each animal was housed in a ventilated plastic cage. Feeds (purina) and litter were periodically replaced and provided, and water was allowed to drink freely. Prior to the initiation of the animal experiment, experiments were conducted at 8 weeks of age through a week of refinement as a period to adapt to the environment of the breeding room.
  • the extract was administered at 100 to 1000 mg / kg. 0.47% (equivalent to 400 mg / kg) and 0.7% (equivalent to 600 mg / kg) were fed to the low fat diet and allowed to freely eat for 2 weeks after pelleting.
  • Blood biochemical test TG (Triglyceride), an enzyme present in hepatocyte, is an enzyme that mainly releases alanine aminotransferase (ALT), alanine aminotransferase (GPT), glutamic pyruvate transaminase, blood urea nitrogen (BUN) and lactate dehydrogenase (LDH) are the standard values of 100 ⁇ 225 IU / L, which is one of the enzymes that acts when the sugar in the cell changes into energy. , Changes of visceral fat distribution by MRI measurement, changes of visceral fat by MRS measurement, and changes of fat by oil red O staining method of liver tissue.
  • FIG. 1 is a graph showing changes in triglyceride in blood and liver tissues when the extract of Panax ginseng is administered to a C57BL / 6JL Lep ob / Lep ob genetic obesity model animal. The concentration of triglyceride in the blood and liver tissues was decreased in a concentration-dependent manner after administration of the extracts.
  • FIG. 2 is a graph showing changes in blood GPT (glutamic pyruvate transaminase), LDH (lactate dehydrogenase) and BUN (blood urea nitrogen) upon administration of the extract of Chenopodium ambrosioides L. at the C57BL / 6JL Lep ob / Lep ob genetic obesity model animal.
  • GPT glutamic pyruvate transaminase
  • LDH lactate dehydrogenase
  • BUN blood urea nitrogen
  • FIG. 3 is a graph showing changes in visceral visceral fat and lipid in liver tissues upon administration of the extract of Chenopodium ambrosioides L. to C57BL / 6JL Lep ob / Lep ob.
  • the distribution of visceral fat in the test group administered with the extract of Radix Salviae Radix was significantly reduced by MRI and MRS measurement compared to the control group.
  • Oil red O staining method As a result of measuring the liver tissue by Oil red O staining method, .
  • Dio (diet induced obesity) C57BL / 6 mouse a high-fat diet-induced model of obesity, was maintained at an average temperature of 20 ° C ⁇ 2 ° C and relative humidity of 60% ⁇ 10% light / dark environment. Each animal was housed in a ventilated plastic cage. Feeds (purina) and litter were periodically replaced and provided, and water was allowed to drink freely. Prior to the initiation of the animal experiment, experiments were conducted through a one week purification period as a period to adapt to the environmental conditions of the breeding room. After induction, obesity was induced by high fat diet for 12 weeks, followed by oral administration of 100 ⁇ 600 mg / kg of fresh water extract once a day for 4 weeks.
  • FIG. 4, FIG. 5, and FIG. 6 show the results of measuring the body weight of the experimental group and the control group.
  • FIG. 4 is a graph showing a decrease in GPT (glutamic pyruvate transaminase), LDH (lactate dehydrogenase) and BUN (blood urea nitrogen) in the case of administration of the extract of Dansamp to DIO (diet-induced obesity)
  • GPT glutamic pyruvate transaminase
  • LDH lactate dehydrogenase
  • BUN blood urea nitrogen
  • FIG. 5 is a graph showing changes in visceral visceral fat in the diet-induced obesity (DIO), which is an induction obesity model animal, in the high fat diet method.
  • DIO diet-induced obesity
  • FIG. 6 is a graph showing change in TG in liver tissue and blood, free fatty acid in blood, and HbA1C during the administration of the extract of Chenopodium ambrosioides (DIO) to diet-induced obesity (DIO).
  • DIO Chenopodium ambrosioides
  • HbA1C diet-induced obesity
  • Body fat reduction rate division Ginseng extract Control group placebo
  • persons median Internal Reduction Rate % persons median Internal Reduction Rate (%) Total fat 7 -6.84 -9.92 + - 7.22 8 0.69 0.65 ⁇ 4.04 Total Tissue 7 -5.41 -6.74 ⁇ 4.57 8 -0.98 -0.53 + - 2.39 Total Mass 7 -3.45 -3.45 + 3.91 8 1.04 1.09 ⁇ 2.13
  • composition for preventing, ameliorating or treating obesity of visceral obesity can be prepared as needed together with a pharmaceutically acceptable carrier containing extract of Radix Salviae.
  • the appropriate dosage of the pharmaceutical composition of the present invention may vary depending on factors such as the formulation method, administration method, age, body weight, sex, pathological condition, food, administration time, administration route, excretion rate, .
  • the pharmaceutical composition for preventing, ameliorating or treating visceral obesity of the present invention can be administered orally or parenterally at the time of clinical administration and can be used in the form of a general pharmaceutical preparation.
  • the composition of the present invention can be administered in various formulations of oral and parenteral administration at the time of actual clinical administration.
  • a diluent such as a filler, an extender, a binder, a wetting agent, a disintegrant and a surfactant, . ≪ / RTI >
  • Solid formulations for oral administration include tablets, pills, powders, granules and capsules, which may contain at least one or more excipients such as starch, calcium carbonate, sucrose, lactose and gelatin And the like.
  • excipients such as starch, calcium carbonate, sucrose, lactose and gelatin And the like.
  • lubricants such as magnesium stearate talc are also used.
  • Liquid preparations for oral administration include suspensions, solutions, emulsions and syrups.
  • Various excipients such as wetting agents, sweetening agents, fragrances and preservatives may be included in addition to water and liquid paraffin, which are simple diluents commonly used. have.
  • Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations and suppositories.
  • the non-aqueous solvent and the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like.
  • injectable ester such as ethyl oleate
  • As the base of the suppository witepsol, macrogol, tween 61, cacao paper, laurin, glycerol and gelatin can be used.
  • the dosage unit may contain, for example, 1, 2, 3 or 4 times the individual dose or may contain 1/2, 1/3 or 1/4 times the dose.
  • the individual dosages preferably contain amounts in which the active drug is administered in one go, which usually corresponds to the full, half, one-third or one-fourth of the daily dose.
  • the effective dose of the extract is preferably from 0.1 mg to 1,000 mg / kg, more preferably from 0.4 to 500 mg / kg, and can be administered 16 times a day. Thus, it may be administered in the range of 0.1 to 6,000 mg / day per kg adult body weight.
  • the present invention provides a health functional food composition for prevention and improvement of visceral obesity obesity comprising an extract of Panax ginseng as an active ingredient.
  • the health functional food refers to a food in which the function of the general food is improved by adding the extract to the general food, and the extract can be added to the general food, or may be prepared by encapsulation, pulverization, suspension or the like.
  • the extract When taken, it takes a certain effect on health, and unlike general medicine, food is used as a raw material, so there is no side effect that may occur when a drug is taken for a long time.
  • the extract of the present invention When used as a food additive, the extract may be added as it is, or may be used together with other food or food ingredients, or may be suitably used according to other conventional methods.
  • the amount of the active ingredient to be mixed can be suitably determined according to its intended use (prevention, health or therapeutic treatment).
  • the extract in general, in the production of a food or beverage mixed with the extract, the extract may be added in an amount of 0.0001 to 50% by weight, preferably 0.1 to 25% by weight based on the total weight of the raw material.
  • the amount can be adjusted to the above-mentioned range.
  • the health food of the present invention when used as the pharmaceutical composition, it is preferable that the health food contains the dried ginseng extract within the measured toxicity range.
  • the food to which the extract can be added include dairy products including meat, sausage, bread, chocolate, candy, snack, confectionery, pizza, ramen, other noodles, gum, powdered milk, , Various soups, drinks, tea, drinks, alcoholic beverages and vitamin complexes.
  • the health foods containing the extracts of Dansamp extract include health food such as juice, tea, jelly, juice, and the like, which are mainly composed of the extract of Panax ginseng, and a folk remedy for edema, nephritis and urethritis .
  • the extract of the present invention When the extract of the present invention is used as a raw material for cosmetics, the extract may be directly added or used in combination with other cosmetic ingredients, and may be suitably used according to a conventional method.
  • the amount of the active ingredient to be mixed can be suitably determined according to the purpose of use thereof. In general, it may be added in an amount of 0.0001 to 10% by weight, preferably 0.1 to 5% by weight, based on the total weight of the raw material in the production of cosmetics using the extract.
  • the cosmetics may be applied to skins, lotions, creams, packs, and color cosmetics, but are not limited thereto.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne une composition pour la prévention, la réduction ou le traitement de l'obésité viscérale, comprenant un extrait de Salvia miltiorrhiza, qui présente une excellente activité en matière de réduction du tissu adipeux viscéral. La présente invention concerne une composition pour la prévention, la réduction ou le traitement de l'obésité viscérale, comprenant un extrait de Salvia miltiorrhiza dont on s'est aperçu qu'il présente une efficacité spécifique contre le tissu adipeux viscéral comme mesuré chez des modèles animaux de souris souffrant d'obésité en raison d'une baisse de la sécrétion de leptine et chez des souris souffrant d'une obésité induite par un régime riche en matières grasses. La présente invention concerne une composition comprenant un extrait de Salvia miltiorrhiza pour la prévention, la réduction ou le traitement de l'obésité viscérale, l'activité inhibitrice de l'extrait de Salvia miltiorrhiza contre l'obésité viscérale étant utilisée pour entraîner un effet de réduction du tissu adipeux viscéral en supprimant la génération de triglycérides TG in vivo dans les tissus hépatiques et le sang et en réduisant l'expression des ALT, LDH, BUN, FFA ou Hb A1C sanguins, comme observé à l'IRM et par spectroscopie de l'hydrogène.
PCT/KR2018/012522 2017-10-31 2018-10-23 Composition contenant un extrait de salvia miltiorrhiza pour la prévention, la réduction ou le traitement de l'obésité viscérale Ceased WO2019088541A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN201880031146.9A CN110612111A (zh) 2017-10-31 2018-10-23 含有丹参提取物的预防、改善或治疗内脏脂肪型肥胖的组合物
JP2019565315A JP2021501119A (ja) 2017-10-31 2018-10-23 丹参抽出物を含む内臓脂肪型肥満予防、改善又は治療組成物
EP18873842.1A EP3705127A4 (fr) 2017-10-31 2018-10-23 Composition contenant un extrait desalvia miltiorrhiza
US16/615,148 US20200171115A1 (en) 2017-10-31 2018-10-23 Composition for preventing or treating visceral fat obesity containing extract of salvia miltiorrhiza radix

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2017-0143582 2017-10-31
KR20170143582 2017-10-31
KR1020180125449A KR102005423B1 (ko) 2017-10-31 2018-10-19 단삼 추출물을 함유하는 내장지방형 비만 예방, 개선 또는 치료 조성물
KR10-2018-0125449 2018-10-19

Publications (2)

Publication Number Publication Date
WO2019088541A2 true WO2019088541A2 (fr) 2019-05-09
WO2019088541A3 WO2019088541A3 (fr) 2019-06-27

Family

ID=66332090

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/012522 Ceased WO2019088541A2 (fr) 2017-10-31 2018-10-23 Composition contenant un extrait de salvia miltiorrhiza pour la prévention, la réduction ou le traitement de l'obésité viscérale

Country Status (1)

Country Link
WO (1) WO2019088541A2 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100818586B1 (ko) 2003-12-30 2008-04-01 주식회사 케이티앤지 대사활성을 촉진시키는 탄시논 유도체를 유효성분으로함유하는 비만 및 대사증후군 치료제

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100854442B1 (ko) * 2006-07-05 2008-08-26 박영준 하엽 추출물 또는 생약복합제 추출물을 함유하는 고지혈증 및 동맥경화증의 예방 및 치료용 조성물
KR101468449B1 (ko) * 2007-04-26 2014-12-04 주식회사 케이티앤지생명과학 신규한 페난스렌퀴논계 화합물 및 이를 포함하는대사증후군 질환의 치료 또는 예방용 약제 조성물
KR101109620B1 (ko) * 2009-04-15 2012-01-31 주식회사 바이오랜드 단삼소납을 함유하는 피부미백 화장료 조성물

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100818586B1 (ko) 2003-12-30 2008-04-01 주식회사 케이티앤지 대사활성을 촉진시키는 탄시논 유도체를 유효성분으로함유하는 비만 및 대사증후군 치료제

Also Published As

Publication number Publication date
WO2019088541A3 (fr) 2019-06-27

Similar Documents

Publication Publication Date Title
KR102005423B1 (ko) 단삼 추출물을 함유하는 내장지방형 비만 예방, 개선 또는 치료 조성물
KR100818586B1 (ko) 대사활성을 촉진시키는 탄시논 유도체를 유효성분으로함유하는 비만 및 대사증후군 치료제
WO2023214716A1 (fr) Composition pharmaceutique et aliment fonctionnel de santé pour la prévention de l'obésité comprenant un extrait de garcinia cambogia
Choi et al. Gentiopicroside isolated from Gentiana scabra Bge. inhibits adipogenesis in 3T3-L1 cells and reduces body weight in diet-induced obese mice
KR101445966B1 (ko) 백두구 추출물을 포함하는 항비만 조성물
KR100863524B1 (ko) 영릉향 추출물을 유효성분으로 함유하는 대사성 질환의예방 및 치료용 조성물
WO2021033994A1 (fr) Composition comprenant un extrait de salvia miltiorrhiza ou de paeonia lactiflora utilisé comme principe actif pour la prévention ou le traitement d'un trouble du métabolisme des lipides
WO2014035035A1 (fr) Composition pharmaceutique contenant un extrait complexe d'aurantii nobilis pericarpium et de crataegus en tant que principe actif, dans le traitement ou la prévention de l'obésité ou de maladies métaboliques d'origine lipidique
EP4043022A1 (fr) Composition destinée à la prévention, à l'amélioration ou au traitement de syndromes métaboliques y compris l'obésité, le diabète, une hyperlipidémie et la stéatose hépatique
WO2019050123A1 (fr) Composition alimentaire pour traiter l'obésité ou l'hyperlipidémie comprenant un extrait de fruit de terminalia chebula et un extrait de phyllanthus emblica
WO2019088541A2 (fr) Composition contenant un extrait de salvia miltiorrhiza pour la prévention, la réduction ou le traitement de l'obésité viscérale
KR20110000452A (ko) 비타민 ｕ를 유효성분으로 함유하는 비만 예방 또는 치료용 조성물
KR100875247B1 (ko) 영릉향 추출물을 유효성분으로 함유하는 대사성 질환의 예방 및 치료용 조성물
WO2017082479A1 (fr) Composition pharmaceutique destinée à la prévention ou au traitement de l'obésité comprenant un extrait embryonnaire de fève germée
KR100967813B1 (ko) 나복자 추출물을 유효성분으로 함유하는 고지혈증 또는비만의 예방 및 치료용 조성물
KR100814949B1 (ko) 민들레 추출물을 함유하는 지질대사 장애 및 당뇨합병증질환의 예방 및 치료용 조성물
WO2013022178A1 (fr) Composition pour prévention et traitement de l'obésité contenant un principe actif sous la forme d'un extrait de préparation végétale mélangée à base de lonicera japonica et d'aurantii nobilis pericarpium fermenté ou non fermenté, et son utilisation
KR20180013716A (ko) 증포발효 인삼열매 추출물을 유효성분으로 함유하는 비만 치료용 조성물
WO2021246703A1 (fr) Composition anti-obésité
KR100706284B1 (ko) 익지인 추출물을 포함하는 지질대사 개선과 비만의예방 및 치료용 약학 조성물
WO2014017741A1 (fr) Composition pharmaceutique contenant de la prunétine en tant que principe actif pour prévenir ou traiter l'obésité ou des maladies métaboliques
WO2019088381A1 (fr) Composition pour la prévention, l'amélioration ou le traitement de l'obésité et de maladies métaboliques, comprenant un extrait complexe de fleur de pêcher et de feuille de lotus
WO2014163262A1 (fr) Composition pour traiter ou prévenir l'obésité, contenant de l'extrait de graines de piment
WO2022149697A1 (fr) Composition antiobésité contenant, en tant que substance active, un produit de fermentation de moringa oleifera préparé au moyen de nouveau monascus purpureus sl1
WO2021066586A1 (fr) Composition pour la prévention, le traitement ou la réduction de l'obésité

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18873842

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2019565315

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018873842

Country of ref document: EP

Effective date: 20200602